Literature DB >> 7661155

Maldigestion associated with exocrine pancreatic insufficiency: implications of gastrointestinal physiology and properties of enzyme preparations for a cause-related and patient-tailored treatment.

M J Bruno1, E B Haverkort, G N Tytgat, D J van Leeuwen.   

Abstract

Clinical conditions in which secondary maldigestion associated with exocrine pancreatic insufficiency occur include chronic pancreatitis, cystic fibrosis, pancreatic cancer, partial or total gastrectomy, and pancreatic resection. Maldigestion can cause serious weight loss, nutritional deficiencies, and subjective complaints associated with steatorrhea. The various causes of exocrine pancreatic insufficiency may be associated with cause-related changes in gastrointestinal physiology, such as changes in gastrointestinal intraluminal pH, bile acid metabolism, gastric emptying, and intestinal motility. Therefore, to optimize the efficacy of treatment, the management of exocrine pancreatic insufficiency must be individually tailored to account for both the underlying cause and any associated disturbance in gastrointestinal physiology. In addition, the properties of the pancreatic enzyme preparations and adjuvant drugs need to be taken into consideration. This paper reviews the pathophysiological mechanisms of maldigestion in exocrine pancreatic insufficiency, discusses the efficacy of different therapy regimens, and gives guidelines for a cause-related and patient-tailored treatment with respect to both drug therapy and dietary counselling.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7661155

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  15 in total

Review 1.  Personalizing protein nourishment.

Authors:  David C Dallas; Megan R Sanctuary; Yunyao Qu; Shabnam Haghighat Khajavi; Alexandria E Van Zandt; Melissa Dyandra; Steven A Frese; Daniela Barile; J Bruce German
Journal:  Crit Rev Food Sci Nutr       Date:  2017-10-13       Impact factor: 11.176

2.  Optimising the therapy of exocrine pancreatic insufficiency by the association of a proton pump inhibitor to enteric coated pancreatic extracts.

Authors:  J E Domínguez-Muñoz; J Iglesias-García; M Iglesias-Rey; M Vilariño-Insua
Journal:  Gut       Date:  2006-07       Impact factor: 23.059

3.  In Vitro Comparison of Physical Parameters, Enzyme Activity, Acid Resistance, and pH Dissolution Characteristics of Enteric-Coated Pancreatic Enzyme Preparations: Implications for Clinical Variability and Pharmacy Substitution.

Authors:  Robert J Kuhn; Sabine Eyting; Friederike Henniges; Andreas Potthoff
Journal:  J Pediatr Pharmacol Ther       Date:  2007-04

Review 4.  Treatment of non-pain-related symptoms.

Authors:  Charles F von Gunten; Ellin Gafford
Journal:  Cancer J       Date:  2013 Sep-Oct       Impact factor: 3.360

5.  Chronic Use of Long-Acting Somatostatin Analogues (SSAs) and Exocrine Pancreatic Insufficiency (EPI) in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): An Under-recognized Adverse Effect.

Authors:  Muhammad Wasif Saif; Alicia Romano; Melissa H Smith; Rachana Patel; Valerie Relias
Journal:  Cancer Med J       Date:  2020-04-27

6.  Monitoring the intragastric distribution of a colloidal drug carrier model by magnetic resonance imaging460.

Authors:  H Faas; W Schwizer; C Feinle; H Lengsfeld; C de Smidt; P Boesiger; M Fried; T Rades
Journal:  Pharm Res       Date:  2001-04       Impact factor: 4.200

Review 7.  Pharmacological challenges in chronic pancreatitis.

Authors:  Anne Estrup Olesen; Anne Brokjaer; Iben Wendelboe Fisher; Isabelle Myriam Larsen
Journal:  World J Gastroenterol       Date:  2013-11-14       Impact factor: 5.742

8.  Gastrointestinal symptoms before and after total pancreatectomy with islet autotransplantation: the role of pancreatic enzyme dosing and adherence.

Authors:  Jill Crosby; Melena D Bellin; David M Radosevich; Srinath Chinnakotla; Ty B Dunn; Timothy L Pruett; Martin L Freeman; Greg J Beilman; Sarah J Schwarzenberg
Journal:  Pancreas       Date:  2015-04       Impact factor: 3.327

9.  Magnetic resonance imaging for the in vivo evaluation of gastric-retentive tablets.

Authors:  Andreas Steingoetter; Dominik Weishaupt; Patrick Kunz; Karsten Mäder; Hans Lengsfeld; Miriam Thumshirn; Peter Boesiger; Michael Fried; Werner Schwizer
Journal:  Pharm Res       Date:  2003-12       Impact factor: 4.200

10.  Delayed release pancrelipase for treatment of pancreatic exocrine insufficiency associated with chronic pancreatitis.

Authors:  Devi Mukkai Krishnamurty; Atoosa Rabiee; Sanjay B Jagannath; Dana K Andersen
Journal:  Ther Clin Risk Manag       Date:  2009-07-12       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.